Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...2526272829303132333435...7475»
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Insights From Survival Analyses During 12 Years of Anti-Vascular Endothelial Growth Factor Therapy for Neovascular Age-Related Macular Degeneration. (Pubmed Central) -  Apr 27, 2021   
    Eyes were excluded from the analysis if they received photodynamic therapy or macular laser, any previous anti-VEGF therapy, treatment with anti-VEGF agents other than ranibizumab or aflibercept, or had an unknown date or visual acuity (VA) value at first injection...These findings demonstrate the potential usefulness of the proposed analyses. This data set, combined with the statistical approach for retrospective analyses, may provide long-term prognostic information for patients newly diagnosed with this condition.
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
    Trial completion date, Trial primary completion date, Monotherapy:  Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov) -  Apr 27, 2021   
    P4,  N=150, Not yet recruiting, 
    ClinicalTrials.gov Identifier: NCT00891735. Trial completion date: Aug 2021 --> Nov 2021 | Trial primary completion date: May 2021 --> Aug 2021
  • ||||||||||  CKD-701 (ranibizumab biosimilar) / Chong Kun Dang
    New P3 trial:  A Study To Evaluate CKD-701 and Lucentis (clinicaltrials.gov) -  Apr 23, 2021   
    P3,  N=312, Completed, 
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Quantifying Conflict of Interest in the Choice of Anti-VEGF Agents. (Pubmed Central) -  Apr 16, 2021   
    To what degree this financial incentive influences ophthalmologists' choice of drugs is unknown, but not trivial. Financial disclosure of the conflicts of interest in the drugs recommended for treatment should be discussed with patients.
  • ||||||||||  Erbitux (cetuximab) / Eli Lilly, EMD Serono, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Identification of potential candidate genes for lip and oral cavity cancer using network analysis. (Pubmed Central) -  Apr 13, 2021   
    Gene enrichment analysis was also performed to identify the gene ontology categorization of cellular components, biological processes, molecular functions, and biological pathways. The genes identified in this study could furnish a new understanding of the underlying molecular mechanisms of carcinogenesis and provide more reliable biomarkers for early diagnosis, prognostication, and treatment of lip and oral cavity cancer.
  • ||||||||||  Ozurdex (dexamethasone intravitreal implant) / AbbVie, Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    [VIRTUAL] The Cost-Effectiveness of Dexamethasone Intravitreal Implant Versus Anti-Vascular Endothelial Growth Factor Therapies for Eyes with a Phakic Lens in UK Clinical Practice () -  Apr 12, 2021 - Abstract #ISPOR2021ISPOR_973;    
    The economic model previously submitted to NICE (TA349) – which assumed a comparator of w&w incurring no costs and included the cost of surgery for the proportion of phakic patients experiencing cataract (based on the ITT population of the MEAD studies, consistent with published observational studies) – was updated using comparator cost assumptions agreed in TA613: a composite comparator of 28% laser, 63% ranibizumab and 9% bevacizumab. Ensuring modelled cost estimates reflect current UK clinical practice as agreed by NICE in 2019, DEX becomes cost saving and is therefore dominant in the DMO phakic population where non-corticosteroid therapy is insufficiently responsive.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Advances in the treatment of diabetic retinopathy. (Pubmed Central) -  Apr 7, 2021   
    The rates of clinically significant DR improvement with ranibizumab could be twice that in the subgroup of patients with moderately severe or severe nonproliferative DR and macular edema. These clinical trial data indicate that intraocular inhibition of VEGF is a rational approach for the management of DR.
  • ||||||||||  Avastin (bevacizumab) / Roche, Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. (Pubmed Central) -  Apr 7, 2021   
    Combination therapy might also reduce the treatment burden with fewer injections in patients with PNV. Switching to intravitreal aflibercept therapy in a cohort of neovascular AMD patients resistant to chronic bevacizumab and/or ranibizumab injections can lead to significant visual improvement in the short term and sustained reduction of central macular thickness over 1 year of followup.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Inflammatory Complications of Intravitreal Anti-VEGF Injections. (Pubmed Central) -  Apr 7, 2021   
    The inflammatory adverse events also share a number of overlapping features, which can make them difficult to discern from one another in a clinical context. This review discusses certain distinguishing features of these conditions that may aid providers in discerning between them and establishing the correct diagnosis.
  • ||||||||||  sozinibercept (OPT-302) / Opthea
    Enrollment open, Combination therapy:  ShORe: OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD) (clinicaltrials.gov) -  Apr 1, 2021   
    P3,  N=990, Recruiting, 
    Results may indicate a rationale for a combination therapy for CSME using both agents, the dexamethasone implant and repeatedly administered ranibizumab injections. Not yet recruiting --> Recruiting
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Journal, Adverse events:  Drug-related adverse effects of antivascular endothelial growth factor agents. (Pubmed Central) -  Mar 27, 2021   
    For patients with CRVO, adding L-CRA as a causal-based treatment to conventional therapy reduced CVP and injection loads and offered improved BCVA.Trial registration number ACTRN12612000004864. Newer anti-VEGF agents pose a significant risk of adverse events not seen with routine anti-VEGF agents.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Neovascular glaucoma in a pediatric patient with neurofibromatosis type 1: a case report. (Pubmed Central) -  Mar 20, 2021   
    We suggest that evaluations of young patients with neovascular glaucoma should include careful attention to the overall condition of the patient and his/her parents, as well as family history. If necessary, NF1 molecular testing should be performed to avoid a missed diagnosis or misdiagnosis.
  • ||||||||||  Eylea (aflibercept intravitreal) / Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Trial completion date, Trial primary completion date:  OPHTH-010915: Aflibercept in Recurrent or Persistent CNV (clinicaltrials.gov) -  Mar 16, 2021   
    P=N/A,  N=80, Recruiting, 
    If necessary, NF1 molecular testing should be performed to avoid a missed diagnosis or misdiagnosis. Trial completion date: Mar 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Sep 2021
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Spectral-Domain OCT Predictors of Visual Outcomes after Ranibizumab Treatment for Macular Edema Resulting from Retinal Vein Occlusion. (Pubmed Central) -  Mar 11, 2021   
    Thus, although longer intervals suggest greater likelihood of not needing retreatment within 1 to 2 months, regular assessment is warranted owing to the unpredictability of nAMD disease activity. Although SD-OCT features may be associated with presenting vision in eyes with macular edema and RVO, most eyes treated with ranibizumab achieve substantial vision gains, and only older age and better baseline BCVA limited visual improvements.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Investigation of genetic base in the treatment of age-related macular degeneration. (Pubmed Central) -  Mar 11, 2021   
    In AMD patients, the efficacy of the antioxidant supplementation and the anti-VEGF therapy appears to differ by genotype. The detection of genetic variants, associated with treatment responsiveness, could lead to improved visual outcomes through genotype-directed therapy.
  • ||||||||||  Avastin (bevacizumab) / Roche, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Intravitreal Therapy for Diabetic Macular Edema: An Update. (Pubmed Central) -  Mar 11, 2021   
    DEX implants are a valuable option for treating DME, although they are usually seen as a second choice, particularly in those eyes that have an insufficient response to anti-VEGF. The new evidence suggested that, in eyes that did not adequately respond to anti-VEGF, switching to a DEX implant at the time to 3 monthly anti-VEGF injections provided better functional outcomes.